Amphastar Pharmaceuticals, Inc. Capital Expenditures
Amphastar Pharmaceuticals, Inc. (AMPH) reported Capital Expenditures of $18.10 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Investing Activities
us-gaap:PaymentsToAcquirePropertyPlantAndEquipment · last filed 2026-08-06
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-06-30 was $8.59M, a 18.68% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2026-03-31 was $9.51M, a 11.12% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-12-31 was $8.27M, a 33.35% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for the quarter ending 2025-09-30 was $5.35M, a 61.23% decline year-over-year.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2025 was $34.88M, a 15.01% decline from fiscal 2024.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2024 was $41.04M, a 7.53% increase from fiscal 2023.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2023 was $38.17M, a 58.80% increase from fiscal 2022.
- Amphastar Pharmaceuticals, Inc. payments to acquire property, plant, and equipment for fiscal 2022 was $24.03M, a 12.46% decline from fiscal 2021.
| Period end | Payments to Acquire Property, Plant, and Equipment 3 month | Payments to Acquire Property, Plant, and Equipment 3 month as first filed | Payments to Acquire Property, Plant, and Equipment 6 month | Payments to Acquire Property, Plant, and Equipment 6 month as first filed | Payments to Acquire Property, Plant, and Equipment 9 month | Payments to Acquire Property, Plant, and Equipment 9 month as first filed | Payments to Acquire Property, Plant, and Equipment 12 month | Payments to Acquire Property, Plant, and Equipment 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $8.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $18.10M 10-Q · filed 2026-08-06 | $26.37M derived: sum of 3 quarters · filed 2026-08-06 | $31.72M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $9.51M 10-Q · filed 2026-05-07 | $17.78M derived: sum of 2 quarters · filed 2026-05-07 | $23.13M derived: sum of 3 quarters · filed 2026-05-07 | $33.69M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | $8.27M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $13.62M derived: sum of 2 quarters · filed 2026-02-26 | $24.18M derived: sum of 3 quarters · filed 2026-08-06 | $34.88M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $5.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $15.91M derived: sum of 2 quarters · filed 2026-08-06 | $26.61M 10-Q · filed 2025-11-06 | $39.02M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | $10.56M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $21.26M 10-Q · filed 2026-08-06 | $33.67M derived: sum of 3 quarters · filed 2026-08-06 | $47.47M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $10.70M 10-Q · filed 2026-05-07 | $23.11M derived: sum of 2 quarters · filed 2026-05-07 | $36.90M derived: sum of 3 quarters · filed 2026-05-07 | $42.95M derived: sum of 4 quarters · filed 2026-05-07 | ||||
| 2024-12-31 | $12.41M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $26.20M derived: sum of 2 quarters · filed 2026-02-26 | $32.25M derived: sum of 3 quarters · filed 2026-02-26 | $41.04M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $13.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $19.84M derived: sum of 2 quarters · filed 2025-11-06 | $28.63M 10-Q · filed 2025-11-06 | $38.07M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-06-30 | $6.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $14.84M 10-Q · filed 2025-08-07 | $24.28M derived: sum of 3 quarters · filed 2026-02-26 | $34.47M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2024-03-31 | $8.79M 10-Q · filed 2025-05-08 | $18.23M derived: sum of 2 quarters · filed 2026-02-26 | $28.43M derived: sum of 3 quarters · filed 2026-02-26 | $37.48M derived: sum of 4 quarters · filed 2026-02-26 | ||||
| 2023-12-31 | $9.44M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $19.64M derived: sum of 2 quarters · filed 2026-02-26 | $28.69M derived: sum of 3 quarters · filed 2026-02-26 | $38.17M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $10.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $19.25M derived: sum of 2 quarters · filed 2024-11-07 | $28.72M 10-Q · filed 2024-11-07 | $35.03M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-06-30 | $9.05M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-09 | $18.53M 10-Q · filed 2024-08-09 | $24.84M derived: sum of 3 quarters · filed 2025-03-03 | $30.46M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2023-03-31 | $9.48M 10-Q · filed 2024-05-10 | $15.79M derived: sum of 2 quarters · filed 2025-03-03 | $21.41M derived: sum of 3 quarters · filed 2025-03-03 | $27.37M derived: sum of 4 quarters · filed 2025-03-03 | ||||
| 2022-12-31 | $6.31M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $11.93M derived: sum of 2 quarters · filed 2025-03-03 | $17.89M derived: sum of 3 quarters · filed 2025-03-03 | $24.03M 10-K · filed 2025-03-03 | ||||
| 2022-09-30 | $5.62M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-08 | $11.59M derived: sum of 2 quarters · filed 2023-11-08 | $17.72M 10-Q · filed 2023-11-08 | $24.60M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-06-30 | $5.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $12.10M 10-Q · filed 2023-08-09 | $18.98M derived: sum of 3 quarters · filed 2024-02-29 | $26.20M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2022-03-31 | $6.14M 10-Q · filed 2023-05-09 | $13.02M derived: sum of 2 quarters · filed 2024-02-29 | $20.24M derived: sum of 3 quarters · filed 2024-02-29 | $25.98M derived: sum of 4 quarters · filed 2024-02-29 | ||||
| 2021-12-31 | $6.88M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | $14.10M derived: sum of 2 quarters · filed 2024-02-29 | $19.84M derived: sum of 3 quarters · filed 2024-02-29 | $27.46M 10-K · filed 2024-02-29 | ||||
| 2021-09-30 | $7.22M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-08 | $12.96M derived: sum of 2 quarters · filed 2022-11-08 | $20.58M 10-Q · filed 2022-11-08 | $29.91M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-06-30 | $5.74M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-09 | $13.36M 10-Q · filed 2022-08-09 | $22.69M derived: sum of 3 quarters · filed 2023-03-01 | $28.32M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2021-03-31 | $7.62M 10-Q · filed 2022-05-10 | $16.95M derived: sum of 2 quarters · filed 2023-03-01 | $22.58M derived: sum of 3 quarters · filed 2023-03-01 | $33.47M derived: sum of 4 quarters · filed 2023-03-01 | ||||
| 2020-12-31 | $9.33M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-01 | $14.96M derived: sum of 2 quarters · filed 2023-03-01 | $25.85M derived: sum of 3 quarters · filed 2023-03-01 | $33.85M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $5.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | $16.52M derived: sum of 2 quarters · filed 2021-11-09 | $24.53M 10-Q · filed 2021-11-09 | $32.94M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2020-06-30 | $10.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | $18.89M 10-Q · filed 2021-08-09 | $27.30M derived: sum of 3 quarters · filed 2022-03-11 | $35.98M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2020-03-31 | $8.01M 10-Q · filed 2021-05-07 | $16.42M derived: sum of 2 quarters · filed 2022-03-11 | $25.09M derived: sum of 3 quarters · filed 2022-03-11 | $34.82M derived: sum of 4 quarters · filed 2022-03-11 | ||||
| 2019-12-31 | $8.41M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $17.09M derived: sum of 2 quarters · filed 2022-03-11 | $26.81M derived: sum of 3 quarters · filed 2022-03-11 | $41.55M 10-K · filed 2022-03-11 | ||||
| 2019-09-30 | $8.68M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-06 | $18.40M derived: sum of 2 quarters · filed 2020-11-06 | $33.15M 10-Q · filed 2020-11-06 | $42.73M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2019-06-30 | $9.72M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | $24.47M 10-Q · filed 2020-08-07 | $34.05M derived: sum of 3 quarters · filed 2021-03-15 | $46.68M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2019-03-31 | $14.74M 10-Q · filed 2020-05-11 | $24.33M derived: sum of 2 quarters · filed 2021-03-15 | $36.96M derived: sum of 3 quarters · filed 2021-03-15 | $49.21M derived: sum of 4 quarters · filed 2021-03-15 | ||||
| 2018-12-31 | $9.58M derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-15 | $22.22M derived: sum of 2 quarters · filed 2021-03-15 | $34.47M derived: sum of 3 quarters · filed 2021-03-15 | $46.81M 10-K · filed 2021-03-15 | ||||
| 2018-09-30 | $12.63M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-08 | $24.89M derived: sum of 2 quarters · filed 2019-11-08 | $37.23M 10-Q · filed 2019-11-08 | $47.34M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-06-30 | $12.25M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-09 | $24.59M 10-Q · filed 2019-08-09 | $34.71M derived: sum of 3 quarters · filed 2020-03-16 | $46.12M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2018-03-31 | $12.34M 10-Q · filed 2019-05-10 | $22.46M derived: sum of 2 quarters · filed 2020-03-16 | $33.87M derived: sum of 3 quarters · filed 2020-03-16 | $40.17M derived: sum of 4 quarters · filed 2020-03-16 | ||||
| 2017-12-31 | $10.12M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-16 | $21.53M derived: sum of 2 quarters · filed 2020-03-16 | $27.83M derived: sum of 3 quarters · filed 2020-03-16 | $35.10M 10-K · filed 2020-03-16 | ||||
| 2017-09-30 | $11.41M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-09 | $17.71M derived: sum of 2 quarters · filed 2018-11-09 | $24.98M 10-Q · filed 2018-11-09 | $30.32M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-06-30 | $6.30M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | $13.57M 10-Q · filed 2018-08-09 | $18.91M derived: sum of 3 quarters · filed 2019-03-15 | $25.61M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2017-03-31 | $7.27M 10-Q · filed 2018-05-10 | $12.60M derived: sum of 2 quarters · filed 2019-03-15 | $19.30M derived: sum of 3 quarters · filed 2019-03-15 | $24.70M derived: sum of 4 quarters · filed 2019-03-15 | ||||
| 2016-12-31 | $5.34M derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-15 | $12.04M derived: sum of 2 quarters · filed 2019-03-15 | $17.44M derived: sum of 3 quarters · filed 2019-03-15 | $21.38M 10-K · filed 2019-03-15 | ||||
| 2016-09-30 | $6.70M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-09 | $12.10M derived: sum of 2 quarters · filed 2017-11-09 | $16.05M 10-Q · filed 2017-11-09 | $14.46M 10-Q · filed 2016-11-09 | $21.36M derived: sum of 4 quarters · filed 2018-03-14 | |||
| 2016-06-30 | $5.40M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-09 | $9.34M 10-Q · filed 2017-08-09 | $8.46M 10-Q · filed 2016-08-09 | $14.65M derived: sum of 3 quarters · filed 2018-03-14 | $18.60M derived: sum of 4 quarters · filed 2018-03-14 | |||
| 2016-03-31 | $3.95M 10-Q · filed 2017-05-10 | $3.53M 10-Q · filed 2016-05-10 | $9.26M derived: sum of 2 quarters · filed 2018-03-14 | $13.20M derived: sum of 3 quarters · filed 2018-03-14 | $16.16M derived: sum of 4 quarters · filed 2018-03-14 | |||
| 2015-12-31 | $5.31M derived: 10-K 12 month − 10-Q 9 month · filed 2018-03-14 | $9.26M derived: sum of 2 quarters · filed 2018-03-14 | $12.22M derived: sum of 3 quarters · filed 2018-03-14 | $16.00M 10-K · filed 2018-03-14 | $14.42M 10-K · filed 2016-03-15 | |||
| 2015-09-30 | $3.94M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-09 | $6.91M derived: sum of 2 quarters · filed 2016-11-09 | $10.69M 10-Q · filed 2016-11-09 | $20.07M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-06-30 | $2.96M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-09 | $6.74M 10-Q · filed 2016-08-09 | $16.12M derived: sum of 3 quarters · filed 2017-03-15 | $20.15M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2015-03-31 | $3.78M 10-Q · filed 2016-05-10 | $13.16M derived: sum of 2 quarters · filed 2017-03-15 | $17.19M derived: sum of 3 quarters · filed 2017-03-15 | $20.25M derived: sum of 4 quarters · filed 2017-03-15 | ||||
| 2014-12-31 | $9.38M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-15 | $13.41M derived: sum of 2 quarters · filed 2017-03-15 | $16.47M derived: sum of 3 quarters · filed 2017-03-15 | $20.50M 10-K · filed 2017-03-15 | $18.67M 10-K · filed 2015-03-26 | |||
| 2014-09-30 | $4.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-13 | $7.09M derived: sum of 2 quarters · filed 2015-11-13 | $11.12M 10-Q · filed 2015-11-13 | $14.86M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-06-30 | $3.06M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-13 | $7.09M 10-Q · filed 2015-08-13 | $10.84M derived: sum of 3 quarters · filed 2016-03-15 | $15.19M derived: sum of 4 quarters · filed 2016-03-15 | ||||
| 2014-03-31 | $4.03M 10-Q · filed 2015-05-14 | $7.78M derived: sum of 2 quarters · filed 2016-03-15 | $12.13M derived: sum of 3 quarters · filed 2016-03-15 | |||||
| 2013-12-31 | $3.75M derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-15 | $8.10M derived: sum of 2 quarters · filed 2016-03-15 | $17.64M 10-K · filed 2016-03-15 | |||||
| 2013-09-30 | $4.35M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-13 | $13.90M 10-Q · filed 2014-11-13 | ||||||
| 2013-06-30 | $9.54M 10-Q · filed 2014-08-13 | |||||||
| 2012-12-31 | $23.13M 10-K · filed 2015-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |
| MANNKIND CORP (MNKD) | United States | $1.058B | -30.41 |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Savara Inc (SVRA) | United States | $1.044B | -9.10 |
| MoonLake Immunotherapeutics (MLTX) | Switzerland | $1.031B | -5.43 |
| Pacira BioSciences, Inc. (PCRX) | United States | $1.020B | 69.03 |
| Janux Therapeutics, Inc. (JANX) | United States | $1.019B | -9.15 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |